Rankings
▼
Calendar
AMLX (Amylyx Pharmaceuticals, Inc.) Stock Financials & Earnings | Market Cap Arena
AMLX
Amylyx Pharmaceuticals, Inc.
Mkt Cap
$1B
Healthcare
·
Biotechnology
·
🇺🇸 United States
·
NASDAQ
Revenue (TTM)
$0
Net Income (TTM)
-$145M
EPS (TTM)
-$1.53
Free Cash Flow (TTM)
-$123M
Gross Margin
—
Op. Margin
—
Net Margin
—
FCF Margin
—
P/S Ratio (TTM)
—
P/E Ratio (TTM)
—
YoY Rev Growth
-100.0%
Employees
—
Earnings Reports
▶
Q4 2025
NEW
Browse All Reports
Next: Q1 2026 · Apr 1
Quarterly
FY
Revenue & Profitability
Revenue
Gross Profit
Operating Income
Quarter
Revenue
Gross Profit
Op. Income
Q1 23
$71M
$66M
-$2M
Q2 23
$98M
$93M
$20M
Q3 23
$103M
$97M
$19M
Q4 23
$108M
$99M
$2M
Q1 24
$89M
-$28M
-$122M
Q2 24
-$1M
-$9M
-$53M
Q3 24
$416K
-$393K
-$76M
Q4 24
-$665K
-$665K
-$41M
Q1 25
$0
$0
-$38M
Q2 25
$0
-$141K
-$43M
Q3 25
$0
-$20M
-$36M
Q4 25
$0
$20M
-$37M
marketcaparena.com
Valuation
P/S Ratio
P/E Ratio
Quarter
P/S
P/E
Q1 23
13.2x
—
Q2 23
6.5x
—
Q3 23
4.2x
674.8x
Q4 23
3.3x
25.1x
Q1 24
3.1x
—
Q2 24
4.1x
—
Q3 24
6.3x
—
Q4 24
14.2x
—
Q1 25
—
—
Q2 25
—
—
Q3 25
—
—
Q4 25
—
—
marketcaparena.com
Operating Cash Flow
Operating Cash Flow
Free Cash Flow
Quarter
Operating CF
Free CF
Q1 23
-$5M
-$5M
Q2 23
$9M
$8M
Q3 23
-$5M
-$6M
Q4 23
$14M
$13M
Q1 24
-$489K
-$556K
Q2 24
-$67M
-$67M
Q3 24
-$42M
-$42M
Q4 24
-$59M
-$59M
Q1 25
-$40M
-$40M
Q2 25
-$25M
-$25M
Q3 25
-$30M
-$30M
Q4 25
-$28M
-$28M
marketcaparena.com
Capital Expenditures
CapEx
Quarter
CapEx
Q1 23
$250K
Q2 23
$278K
Q3 23
$357K
Q4 23
$356K
Q1 24
$67K
Q2 24
$89K
Q3 24
$19K
Q4 24
$20K
Q1 25
$11K
Q2 25
$17K
Q3 25
$24K
Q4 25
$86K
marketcaparena.com
OpEx vs Revenue Growth (YoY)
Revenue Growth
OpEx Growth
Quarter
Revenue Growth
OpEx Growth
Q1 23
—
+53.7%
Q2 23
—
+43.8%
Q3 23
+29666.1%
+52.6%
Q4 23
+395.5%
+60.2%
Q1 24
+24.1%
+186.8%
Q2 24
-101.0%
-32.8%
Q3 24
-99.6%
-9.4%
Q4 24
-100.6%
-62.5%
Q1 25
-100.0%
-82.1%
Q2 25
+100.0%
-18.2%
Q3 25
-100.0%
-52.6%
Q4 25
+100.0%
-8.5%
marketcaparena.com
Stock-Based Compensation
SBC ($)
% of Revenue
Quarter
SBC ($)
% of Revenue
Q1 23
$8M
10.5%
Q2 23
$10M
10.1%
Q3 23
$10M
9.9%
Q4 23
$10M
8.8%
Q1 24
$10M
11.2%
Q2 24
$10M
—
Q3 24
$7M
1635.3%
Q4 24
$7M
—
Q1 25
$7M
—
Q2 25
$7M
—
Q3 25
$7M
—
Q4 25
$6M
—
marketcaparena.com
OpEx Breakdown
R&D
G&A
SG&A
Quarter
R&D
G&A
SG&A
Q1 23
$24M
$44M
—
Q2 23
$29M
—
$43M
Q3 23
$30M
—
$49M
Q4 23
$45M
—
$52M
Q1 24
$37M
—
$58M
Q2 24
$23M
—
$22M
Q3 24
$21M
—
$18M
Q4 24
$23M
—
$17M
Q1 25
$22M
—
$16M
Q2 25
$27M
—
$16M
Q3 25
$20M
—
$16M
Q4 25
$21M
—
$15M
marketcaparena.com
War Chest
Cash & Equivalents
Short-Term Investments
Quarter
Cash
Short-term Investments
Total
Q1 23
$115M
$231M
$346M
Q2 23
$248M
$110M
$357M
Q3 23
$135M
$220M
$355M
Q4 23
$170M
$201M
$371M
Q1 24
$171M
$203M
$373M
Q2 24
$75M
$235M
$310M
Q3 24
$72M
$163M
$234M
Q4 24
$77M
$99M
$177M
Q1 25
$60M
$144M
$204M
Q2 25
$58M
$123M
$181M
Q3 25
$225M
$119M
$344M
Q4 25
$227M
$90M
$317M
marketcaparena.com
Shares Outstanding
Shares Outstanding
Quarter
Shares (Diluted)
QoQ Change
Q1 23
71M
+8.3%
Q2 23
70M
-1.0%
Q3 23
70M
-0.5%
Q4 23
69M
-0.8%
Q1 24
68M
-1.9%
Q2 24
68M
+0.3%
Q3 24
68M
+0.1%
Q4 24
69M
+0.7%
Q1 25
86M
+24.9%
Q2 25
89M
+4.0%
Q3 25
93M
+4.7%
Q4 25
95M
+1.3%
marketcaparena.com
Revenue Per Employee
Revenue / Employee
Year
Revenue/Employee
Employees
FY 19
—
—
FY 20
—
—
FY 21
$0
205
FY 22
$85K
262
FY 23
$992K
384
FY 24
$710K
123
FY 25
$0
160K
marketcaparena.com